Academic Journal

CAR T-cells for colorectal cancer immunotherapy: Ready to go?

Bibliographic Details
Title: CAR T-cells for colorectal cancer immunotherapy: Ready to go?
Authors: Ghazi B; Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco., El Ghanmi A; Mohammed VI International University Hospital, Faculty of Medicine, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco., Kandoussi S; Immuno-Genetics and Human Pathology Laboratory, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco., Ghouzlani A; Immuno-Genetics and Human Pathology Laboratory, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco., Badou A; Immuno-Genetics and Human Pathology Laboratory, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.
Source: Frontiers in immunology [Front Immunol] 2022 Nov 15; Vol. 13, pp. 978195. Date of Electronic Publication: 2022 Nov 15 (Print Publication: 2022).
Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't
Language: English
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Imprint Name(s): Original Publication: [Lausanne : Frontiers Research Foundation]
MeSH Terms: Immunotherapy* , Colorectal Neoplasms*/therapy, Humans ; Immunologic Factors ; Immunotherapy, Adoptive/adverse effects ; T-Lymphocytes ; Tumor Microenvironment
Abstract: Chimeric antigen receptor (CAR) T-cells represent a new genetically engineered cell-based immunotherapy tool against cancer. The use of CAR T-cells has revolutionized the therapeutic approach for hematological malignancies. Unfortunately, there is a long way to go before this treatment can be developed for solid tumors, including colorectal cancer. CAR T-cell therapy for colorectal cancer is still in its early stages, and clinical data are scarce. Major limitations of this therapy include high toxicity, relapses, and an impermeable tumor microenvironment for CAR T-cell therapy in colorectal cancer. In this review, we summarize current knowledge, highlight challenges, and discuss perspectives regarding CAR T-cell therapy in colorectal cancer.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Ghazi, El Ghanmi, Kandoussi, Ghouzlani and Badou.)
References: Int J Mol Sci. 2021 Oct 29;22(21):. (PMID: 34769211)
J Immunol. 2009 Jun 1;182(11):6744-52. (PMID: 19454669)
Clin Cancer Res. 2012 May 1;18(9):2478-89. (PMID: 22371455)
Sci Rep. 2021 Nov 2;11(1):21504. (PMID: 34728682)
Front Immunol. 2019 Feb 05;10:128. (PMID: 30804938)
Cancers (Basel). 2019 Jan 07;11(1):. (PMID: 30621018)
Clin Cancer Res. 2012 Dec 1;18(23):6436-45. (PMID: 23032741)
J Leukoc Biol. 2019 Feb;105(2):243-255. (PMID: 30387907)
Front Immunol. 2021 Jul 09;12:679425. (PMID: 34305910)
Nat Immunol. 2017 Feb 15;18(3):255-262. (PMID: 28198830)
J Clin Invest. 2016 Oct 3;126(10):3814-3826. (PMID: 27571406)
N Engl J Med. 2014 Dec 4;371(23):2189-2199. (PMID: 25409260)
Mol Ther. 2017 May 3;25(5):1248-1258. (PMID: 28366766)
Nature. 2014 Nov 27;515(7528):577-81. (PMID: 25428507)
N Engl J Med. 2017 Nov 16;377(20):1919-1929. (PMID: 28885881)
Front Immunol. 2020 Sep 30;11:565631. (PMID: 33101285)
Nat Rev Gastroenterol Hepatol. 2013 Oct;10(10):607-20. (PMID: 23856888)
Int J Cancer. 2020 May 1;146(9):2531-2538. (PMID: 31396956)
Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S2-5. (PMID: 23085599)
Cancer Gene Ther. 2000 Feb;7(2):284-91. (PMID: 10770638)
Biochem Cell Biol. 2019 Apr;97(2):85-90. (PMID: 30273495)
Sci Transl Med. 2019 Jul 17;11(501):. (PMID: 31316010)
Clin Cancer Res. 2016 Apr 15;22(8):1865-74. (PMID: 27084740)
J Immunother Cancer. 2018 May 14;6(1):35. (PMID: 29754585)
Oncoimmunology. 2020 Nov 25;9(1):1846926. (PMID: 33312759)
J Mol Biol. 2007 Jul 6;370(2):220-30. (PMID: 17512947)
Science. 2015 Oct 9;350(6257):207-211. (PMID: 26359337)
Cancers (Basel). 2019 Dec 23;12(1):. (PMID: 31878090)
Cells. 2020 Feb 27;9(3):. (PMID: 32121014)
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14827-32. (PMID: 8962140)
Hum Pathol. 2005 Feb;36(2):170-9. (PMID: 15754294)
Expert Rev Anticancer Ther. 2018 Oct;18(10):991-1006. (PMID: 30019590)
Cell Death Dis. 2021 Nov 27;12(12):1109. (PMID: 34839348)
Front Immunol. 2021 Oct 13;12:762341. (PMID: 34721435)
Science. 2015 Apr 3;348(6230):124-8. (PMID: 25765070)
Immunotherapy. 2019 Feb;11(3):201-213. (PMID: 30730277)
Cancer Cell. 2018 Dec 10;34(6):1012-1026.e3. (PMID: 30537506)
Cancer Gene Ther. 2020 May;27(5):341-355. (PMID: 31155611)
Cancer Lett. 2015 Aug 28;365(1):23-9. (PMID: 25980820)
Cancer Cell. 2015 Apr 13;27(4):437-8. (PMID: 25873170)
World J Gastroenterol. 2016 Aug 14;22(30):6876-89. (PMID: 27570424)
J Cancer. 2021 Sep 13;12(22):6629-6639. (PMID: 34659553)
Nat Biotechnol. 2019 Sep;37(9):1049-1058. (PMID: 31332324)
Cancer Cell. 2012 Dec 11;22(6):699-701. (PMID: 23238008)
Nature. 2012 Feb 08;482(7385):400-4. (PMID: 22318521)
N Engl J Med. 2018 Jul 5;379(1):64-73. (PMID: 29972754)
Invest New Drugs. 2020 Dec;38(6):1888-1898. (PMID: 32488569)
Mol Ther. 2011 Mar;19(3):620-6. (PMID: 21157437)
Vaccines (Basel). 2020 Jul 10;8(3):. (PMID: 32664247)
Expert Rev Precis Med Drug Dev. 2021;6(2):117-129. (PMID: 34027103)
Mol Med Rep. 2019 Sep;20(3):2355-2364. (PMID: 31322180)
World J Gastroenterol. 2020 Apr 7;26(13):1394-1426. (PMID: 32308343)
Mol Ther. 2010 Feb;18(2):413-20. (PMID: 19773745)
Br J Cancer. 2005 May 9;92(9):1746-53. (PMID: 15856045)
J Cancer. 2021 Jan 21;12(6):1804-1814. (PMID: 33613769)
Onco Targets Ther. 2018 Aug 21;11:5047-5057. (PMID: 30174443)
Curr Opin Immunol. 2014 Apr;27:8-15. (PMID: 24487185)
Nature. 2014 Nov 27;515(7528):572-6. (PMID: 25428506)
Front Oncol. 2020 Aug 26;10:1594. (PMID: 32984022)
Clin Cancer Res. 2018 Jun 1;24(11):2473-2481. (PMID: 29386217)
Cancer Lett. 2014 Aug 28;351(1):151-61. (PMID: 24880079)
Cancer Res. 2016 Jul 15;76(14):4090-9. (PMID: 27287716)
Cell. 2015 Jan 15;160(1-2):48-61. (PMID: 25594174)
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13255-60. (PMID: 11687624)
Front Immunol. 2022 Jun 01;13:883694. (PMID: 35720311)
Oncoimmunology. 2016 Sep 2;5(10):e1227897. (PMID: 27853651)
Nat Genet. 2013 Jan;45(1):98-103. (PMID: 23202126)
Front Immunol. 2019 Oct 11;10:2250. (PMID: 31681259)
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8. (PMID: 2513569)
Cancer. 2019 Dec 1;125(23):4139-4147. (PMID: 31433498)
Biomark Med. 2015;9(4):363-75. (PMID: 25808440)
Oncotarget. 2017 Feb 21;8(8):13545-13559. (PMID: 28088790)
Cancer Lett. 2018 Oct 1;433:165-175. (PMID: 29981429)
Curr Opin Immunol. 2018 Apr;51:55-61. (PMID: 29525346)
J Natl Compr Canc Netw. 2022 Feb;20(2):167-192. (PMID: 35130500)
J Hematol Oncol. 2018 Apr 23;11(1):58. (PMID: 29685162)
Am J Pathol. 2001 Jul;159(1):297-304. (PMID: 11438476)
Front Oncol. 2021 Feb 02;10:608609. (PMID: 33604291)
Front Oncol. 2020 Jun 24;10:885. (PMID: 32670871)
Mol Ther Oncolytics. 2021 Feb 24;20:556-568. (PMID: 33738341)
J Oncol. 2021 Jul 6;2021:9918116. (PMID: 34326875)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
Mol Ther. 2010 Apr;18(4):843-51. (PMID: 20179677)
Clin Cancer Res. 2012 Dec 15;18(24):6758-70. (PMID: 23032743)
Cancers (Basel). 2019 Feb 06;11(2):. (PMID: 30736355)
Front Immunol. 2021 Oct 28;12:765097. (PMID: 34777381)
Best Pract Res Clin Haematol. 2018 Jun;31(2):176-183. (PMID: 29909918)
J Natl Compr Canc Netw. 2021 Mar 02;19(3):329-359. (PMID: 33724754)
J Immunother Cancer. 2019 Jul 15;7(1):183. (PMID: 31307554)
Mol Cell. 2019 Nov 7;76(3):359-370. (PMID: 31668929)
J Clin Oncol. 2018 Oct 20;36(30):2978-2979. (PMID: 30179566)
J Thorac Dis. 2018 Aug;10(8):4689-4693. (PMID: 30233840)
Mol Cancer. 2011 Aug 31;10:106. (PMID: 21880146)
Cancer Immunol Res. 2016 Nov;4(11):959-967. (PMID: 27671167)
Prz Gastroenterol. 2019;14(2):89-103. (PMID: 31616522)
J Hematol Oncol. 2017 Jan 5;10(1):4. (PMID: 28057014)
Front Immunol. 2020 Feb 26;11:326. (PMID: 32194561)
J Surg Res. 2022 Apr;272:37-50. (PMID: 34929499)
Hepatology. 2009 Nov;50(5):1453-63. (PMID: 19676131)
Nature. 2014 Aug 21;512(7514):324-7. (PMID: 25043048)
Clin Cancer Res. 2021 Sep 1;27(17):4680-4684. (PMID: 33846198)
Cancer Res. 2015 Aug 1;75(15):3043-53. (PMID: 26054597)
Oncoimmunology. 2018 May 7;7(7):e1440169. (PMID: 29900044)
Biochem J. 2009 Dec 10;424(3):449-58. (PMID: 19747165)
Signal Transduct Target Ther. 2020 Mar 20;5(1):22. (PMID: 32296018)
N Engl J Med. 2015 May 21;372(21):2018-28. (PMID: 25891174)
Cancer Metastasis Rev. 2020 Sep;39(3):969-987. (PMID: 32507912)
Nat Med. 2018 May;24(5):541-550. (PMID: 29686425)
Front Immunol. 2022 May 11;13:795164. (PMID: 35634281)
Mol Ther. 2019 Oct 2;27(10):1825-1835. (PMID: 31331813)
Front Oncol. 2018 Aug 03;8:237. (PMID: 30123774)
Mol Cancer. 2017 Mar 14;16(1):63. (PMID: 28288645)
Front Oncol. 2020 Jul 28;10:1243. (PMID: 32850376)
Front Oncol. 2020 May 06;10:697. (PMID: 32435621)
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96. (PMID: 24556840)
Gut. 2017 Apr;66(4):683-691. (PMID: 26818619)
Hum Gene Ther. 2019 Apr;30(4):402-412. (PMID: 30693795)
Clin Cancer Res. 2009 Sep 1;15(17):5379-88. (PMID: 19706802)
Int J Mol Sci. 2017 Jun 21;18(6):. (PMID: 28635639)
Nat Med. 2013 Jun;19(6):747-52. (PMID: 23644516)
Biochem J. 2012 Mar 1;442(2):293-302. (PMID: 21999204)
BMJ Open. 2017 Nov 12;7(11):e017075. (PMID: 29133316)
Immunity. 2019 Jun 18;50(6):1498-1512.e5. (PMID: 31097342)
J Exp Clin Cancer Res. 2022 Mar 31;41(1):119. (PMID: 35361234)
Blood. 2014 Jul 17;124(3):453-62. (PMID: 24891321)
Front Pharmacol. 2021 Nov 01;12:724306. (PMID: 34790117)
Front Oncol. 2021 Jan 06;10:574860. (PMID: 33489881)
Expert Opin Investig Drugs. 2019 Jan;28(1):29-38. (PMID: 30513002)
Ann N Y Acad Sci. 2000;915:136-43. (PMID: 11193569)
Cells. 2020 Apr 03;9(4):. (PMID: 32260097)
N Engl J Med. 2017 Dec 21;377(25):2500-2501. (PMID: 29262275)
Nat Rev Drug Discov. 2019 Mar;18(3):197-218. (PMID: 30610226)
J Clin Oncol. 2013 Nov 10;31(32):e439-42. (PMID: 24043743)
Ann Oncol. 2019 Jan 1;30(1):44-56. (PMID: 30395155)
Int J Mol Sci. 2019 Apr 17;20(8):. (PMID: 30999624)
Nat Rev Cancer. 2012 Mar 15;12(4):298-306. (PMID: 22419253)
Nat Rev Immunol. 2015 Aug;15(8):486-99. (PMID: 26205583)
Front Oncol. 2020 May 27;10:849. (PMID: 32670869)
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758. (PMID: 30787022)
Front Immunol. 2020 Sep 24;11:531491. (PMID: 33072086)
Cancer Res. 2012 Mar 1;72(5):1081-91. (PMID: 22237626)
Cancer Immunol Res. 2018 May;6(5):509-516. (PMID: 29615399)
Immunity. 2013 Oct 17;39(4):782-95. (PMID: 24138885)
J Exp Med. 2014 Oct 20;211(11):2231-48. (PMID: 25245761)
Cancer Cell. 2015 Dec 14;28(6):690-714. (PMID: 26678337)
Gastroenterology. 2008 May;134(5):1296-310. (PMID: 18471507)
Sci Transl Med. 2017 Jul 19;9(399):. (PMID: 28724573)
Cancer Cell Int. 2019 Aug 7;19:209. (PMID: 31406485)
Semin Oncol. 2015 Aug;42(4):663-71. (PMID: 26320069)
Int J Cancer. 1995 Apr 10;61(2):272-9. (PMID: 7705958)
Cancer Immunol Res. 2018 Jan;6(1):14-24. (PMID: 29097422)
N Engl J Med. 2011 Jun 30;364(26):2517-26. (PMID: 21639810)
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5002-7. (PMID: 15047891)
J Biomed Sci. 2017 Apr 4;24(1):26. (PMID: 28376884)
Front Oncol. 2021 Aug 06;11:720501. (PMID: 34422667)
Front Oncol. 2020 Oct 16;10:588134. (PMID: 33178614)
Nature. 2017 Jan 18;541(7637):321-330. (PMID: 28102259)
Nat Med. 2015 Jan;21(1):81-5. (PMID: 25531942)
Ann Oncol. 2016 Aug;27(8):1386-422. (PMID: 27380959)
J Hematol Oncol. 2022 Jul 16;15(1):95. (PMID: 35842707)
J Immunother Cancer. 2017 Mar 21;5:22. (PMID: 28344808)
Front Biosci (Landmark Ed). 2020 Jun 1;25(9):1765-1786. (PMID: 32472757)
J Immunol Res. 2018 Oct 15;2018:4263520. (PMID: 30410941)
J Clin Oncol. 2015 May 20;33(15):1688-96. (PMID: 25800760)
Nat Rev Clin Oncol. 2021 Feb;18(2):63. (PMID: 33349691)
Cancers (Basel). 2022 Mar 09;14(6):. (PMID: 35326556)
J Immunother Cancer. 2020 Aug;8(2):. (PMID: 32843493)
Am J Pathol. 1999 Jun;154(6):1805-13. (PMID: 10362805)
Biochem Biophys Res Commun. 2013 May 3;434(2):352-6. (PMID: 23558291)
N Engl J Med. 2015 Jul 9;373(2):123-35. (PMID: 26028407)
Cancer Lett. 2021 Feb 1;498:201-209. (PMID: 33129958)
Cancer Cell. 2017 Mar 13;31(3):311-325. (PMID: 28292435)
Cancer. 2007 Aug 15;110(4):926-35. (PMID: 17580361)
Nature. 2012 Jul 5;487(7405):64-9. (PMID: 22763440)
Ther Adv Med Oncol. 2015 May;7(3):153-69. (PMID: 26673925)
Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. (PMID: 28660319)
Front Cell Dev Biol. 2020 Oct 15;8:569219. (PMID: 33178688)
Cancer Med. 2012 Aug;1(1):5-16. (PMID: 23342249)
Front Immunol. 2018 Mar 12;9:476. (PMID: 29662484)
J Int Med Res. 2012;40(6):2109-16. (PMID: 23321167)
J Immunol. 2008 May 15;180(10):7028-38. (PMID: 18453625)
Curr Cancer Drug Targets. 2018;18(9):857-868. (PMID: 29295696)
Mol Ther. 2020 Nov 4;28(11):2320-2339. (PMID: 32979309)
Nat Cancer. 2022 May;3(5):581-594. (PMID: 35314826)
Int J Mol Sci. 2019 Mar 14;20(6):. (PMID: 30875739)
Trends Cancer. 2020 Jul;6(7):605-618. (PMID: 32610070)
Am J Cancer Res. 2019 May 01;9(5):945-958. (PMID: 31218103)
Clin Dev Immunol. 2012;2012:238924. (PMID: 22481963)
Sci Rep. 2017 Oct 30;7(1):14366. (PMID: 29085043)
Front Oncol. 2021 Jun 23;11:657545. (PMID: 34249693)
Crit Rev Oncol Hematol. 2022 Jan;169:103538. (PMID: 34801700)
Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308)
Cancer Lett. 2015 Oct 28;367(2):103-7. (PMID: 26188281)
Cancer Immunol Res. 2015 Jun;3(6):575-82. (PMID: 26041808)
Biomedicines. 2021 Apr 07;9(4):. (PMID: 33917081)
Curr Opin Virol. 2016 Dec;21:9-15. (PMID: 27379906)
Mol Cancer Res. 2008 Feb;6(2):186-93. (PMID: 18245228)
Immunother Adv. 2021 Aug 13;1(1):ltab018. (PMID: 34604863)
Immunity. 2018 Dec 18;49(6):1148-1161.e7. (PMID: 30552023)
Nat Biotechnol. 2019 Dec;37(12):1425-1434. (PMID: 31160723)
Front Immunol. 2020 May 15;11:940. (PMID: 32499786)
J Immunother. 2019 Feb/Mar;42(2):33-42. (PMID: 30586347)
Mol Ther Oncolytics. 2020 May 04;17:421-430. (PMID: 32462079)
Cancer Med. 2019 Aug;8(10):4753-4765. (PMID: 31237116)
J Pathol Clin Res. 2021 Nov;7(6):577-589. (PMID: 34363325)
Contributed Indexing: Keywords: CAR T cells; clinical data; colorectal cancer; immunotherapies; tumor microenvironement; tumor mutational burden
Substance Nomenclature: 0 (Immunologic Factors)
Entry Date(s): Date Created: 20221202 Date Completed: 20221205 Latest Revision: 20221205
Update Code: 20221216
PubMed Central ID: PMC9705989
DOI: 10.3389/fimmu.2022.978195
PMID: 36458008
Database: MEDLINE
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2022.978195